Canakinumab treatment for patients with active recurrent or chronic tnf receptor-associated periodic syndrome (traps): an open-label, phase ii study
Gattorno, Marco Obici, Laura Cattalini, Marco Tormey, Vincent Abrams, Ken Davis, Nicole Speziale, Antonio Bhansali, Suraj G Martini, Alberto Lachmann, Helen J
Gattorno, Marco
Obici, Laura
Cattalini, Marco
Tormey, Vincent
Abrams, Ken
Davis, Nicole
Speziale, Antonio
Bhansali, Suraj G
Martini, Alberto
Lachmann, Helen J
Identifiers
http://hdl.handle.net/10379/11593
https://doi.org/10.13025/28816
https://doi.org/10.13025/28816
Repository DOI
Publication Date
2016-06-07
Type
Article
Downloads
Citation
Gattorno, Marco; Obici, Laura; Cattalini, Marco; Tormey, Vincent; Abrams, Ken; Davis, Nicole; Speziale, Antonio; Bhansali, Suraj G; Martini, Alberto; Lachmann, Helen J (2016). Canakinumab treatment for patients with active recurrent or chronic tnf receptor-associated periodic syndrome (traps): an open-label, phase ii study. Annals of the Rheumatic Diseases 76 (1), 173-178
Abstract
Objective To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1 beta antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Methods Twenty patients (aged 7-78 years) with active recurrent or chronic TRAPS were treated with canakinumab 150 mg every 4 weeks for 4 months (2 mg/kg for those 40 kg) in this open-label, proof-of-concept, phase II study. Canakinumab was then withdrawn for up to 5 months, with reintroduction on relapse, and 4 weekly administration (subsequently increased to every 8 weeks) for 24 months. The primary efficacy variable was the proportion of patients achieving complete or almost complete response at day 15, defined as clinical remission (Physician's Global Assessment score <= 1) and full or partial serological remission. Results Nineteen patients (19/20, 95%; 95% CI 75.1% to 99.9%) achieved the primary efficacy variable. Responses to canakinumab occurred rapidly; median time to clinical remission 4 days (95% CI 3 to 8 days). All patients relapsed after canakinumab was withdrawn; median time to relapse 91.5 days (95% CI 65 to 117 days). On reintroduction of canakinumab, clinical and serological responses were similar to those seen during the first phase, and were sustained throughout treatment. Canakinumab was well tolerated and clinical responses were accompanied by rapid and sustained improvement in health-related quality of life. Weight normalised pharmacokinetics of canakinumab, although limited, appeared to be consistent with historical canakinumab data. Conclusions Canakinumab induces rapid disease control in patients with active TRAPS, and clinical benefits are sustained during long-term treatment.
Funder
Publisher
BMJ
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland